STELARA Solution for injection Ref.[108324] Active ingredients: Ustekinumab

Source: FDA, National Drug Code (US)  Revision Year: 2022 

1. Indications and Usage

1.1 Psoriasis (Ps)

STELARA is indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

1.2 Psoriatic Arthritis (PsA)

STELARA is indicated for the treatment of patients 6 years or older with active psoriatic arthritis.

1.3 Crohn’s Disease (CD)

STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease.

1.4 Ulcerative Colitis

STELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

2. Dosage and Administration

2.1 Psoriasis

Subcutaneous Adult Dosage Regimen

  • For patients weighing 100 kg or less, the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
  • For patients weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.

In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects [see Clinical Studies (14)].

Subcutaneous Pediatric Dosage Regimen

Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.

The recommended dose of STELARA for pediatric patients (6–17 years old) based on body weight is shown below (Table 1).

Table 1. Recommended Dose of STELARA for Subcutaneous Injection in Pediatric Patients (6–17 years old) with Psoriasis:

Body Weight of Patient at the
Time of Dosing
Recommended Dose
less than 60 kg 0.75 mg/kg
60 kg to 100 kg 45 mg
more than 100 kg 90 mg

For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the single-dose vial.

Table 2. Injection volumes of STELARA 45 mg/0.5 mL single-dose vials for pediatric patients (6–17 years old) with psoriasis and pediatric patients (6–17 years old) with psoriatic arthritis* weighing less than 60 kg:

Body Weight
(kg) at the
time of dosing
Dose (mg) Volume of
injection (mL)
15 11.3 0.12
16 12.0 0.13
17 12.8 0.14
18 13.5 0.15
19 14.3 0.16
20 15.0 0.17
21 15.8 0.17
22 16.5 0.18
23 17.3 0.19
24 18.0 0.20
25 18.8 0.21
26 19.5 0.22
27 20.3 0.22
28 21.0 0.23
29 21.8 0.24
30 22.5 0.25
31 23.3 0.26
32 24 0.27
33 24.8 0.27
34 25.5 0.28
35 26.3 0.29
36 27 0.3
37 27.8 0.31
38 28.5 0.32
39 29.3 0.32
40 30 0.33
41 30.8 0.34
42 31.5 0.35
43 32.3 0.36
44 33 0.37
45 33.8 0.37
46 34.5 0.38
47 35.3 0.39
48 36 0.4
49 36.8 0.41
50 37.5 0.42
51 38.3 0.42
52 39 0.43
53 39.8 0.44
54 40.5 0.45
55 41.3 0.46
56 42 0.46
57 42.8 0.47
58 43.5 0.48
59 44.3 0.49

* Refer to 2.2 Psoriatic Arthritis; Subcutaneous Pediatric Dosage Regimen.

2.2 Psoriatic Arthritis

Subcutaneous Adult Dosage Regimen

  • The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
  • For patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.

Subcutaneous Pediatric Dosage Regimen

Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.

The recommended dose of STELARA for pediatric patients (6 to 17 years old) with psoriatic arthritis, based on body weight, is shown below (Table 3).

Table 3. Recommended Dose of STELARA for Subcutaneous Injection in Pediatric Patients (6 to 17 years old) with Psoriatic Arthritis:

Body Weight of Patient at the Time
of Dosing
Recommended Dose
less than 60 kg* 0.75 mg/kg
60 kg or more 45 mg
greater than 100 kg with co-existent
moderate-to-severe plaque psoriasis
90 mg

* For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the single-dose vial.

2.3 Crohn’s Disease and Ulcerative Colitis

Intravenous Induction Adult Dosage Regimen

A single intravenous infusion dose of STELARA using the weight-based dosage regimen specified in Table 4 [see Instructions for dilution of STELARA 130 mg vial for intravenous infusion (2.6)].

Table 4. Initial Intravenous Dosage of STELARA:

Body Weight of
Patient at the time of
dosing
Dose Number of 130 mg/26 mL
(5 mg/mL) STELARA vials
55 kg or less 260 mg 2
more than 55 kg to 85 kg 390 mg 3
more than 85 kg 520 mg 4

Subcutaneous Maintenance Adult Dosage Regimen

The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

2.4 General Considerations for Administration

  • STELARA is intended for use under the guidance and supervision of a physician. STELARA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. The appropriate dose should be determined by a healthcare provider using the patient’s current weight at the time of dosing. In pediatric patients, it is recommended that STELARA be administered by a healthcare provider. If a physician determines that it is appropriate, a patient may self-inject or a caregiver may inject STELARA after proper training in subcutaneous injection technique. Patients should be instructed to follow the directions provided in the Medication Guide [see Medication Guide].
  • The needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex). The needle cover should not be handled by persons sensitive to latex.
  • It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. When using the single-dose vial, a 1 mL syringe with a 27 gauge, ½ inch needle is recommended.
  • Prior to administration, visually inspect STELARA for particulate matter and discoloration. STELARA is a colorless to light yellow solution and may contain a few small translucent or white particles. Do not use STELARA if it is discolored or cloudy, or if other particulate matter is present. STELARA does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.

2.5 Instructions for Administration of STELARA Prefilled Syringes Equipped with Needle Safety Guard

Refer to the diagram below for the provided instructions.

To prevent premature activation of the needle safety guard, do not touch the NEEDLE GUARD ACTIVATION CLIPS at any time during use.

  • Hold the BODY and remove the NEEDLE COVER. Do not hold the PLUNGER or PLUNGER HEAD while removing the NEEDLE COVER or the PLUNGER may move. Do not use the prefilled syringe if it is dropped without the NEEDLE COVER in place.
  • Inject STELARA subcutaneously as recommended [see Dosage and Administration (2.1, 2.2, 2.3)].
  • Inject all of the medication by pushing in the PLUNGER until the PLUNGER HEAD is completely between the needle guard wings. Injection of the entire prefilled syringe contents is necessary to activate the needle guard.

  • After injection, maintain the pressure on the PLUNGER HEAD and remove the needle from the skin. Slowly take your thumb off the PLUNGER HEAD to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by the illustration below:

  • Used syringes should be placed in a puncture-resistant container.

2.6 Preparation and Administration of STELARA 130 mg/26 mL (5 mg/mL) Vial for Intravenous Infusion (Crohn’s Disease and Ulcerative Colitis)

STELARA solution for intravenous infusion must be diluted, prepared and infused by a healthcare professional using aseptic technique.

  1. Calculate the dose and the number of STELARA vials needed based on patient weight (Table 4). Each 26 mL vial of STELARA contains 130 mg of ustekinumab.
  2. Withdraw, and then discard a volume of the 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag equal to the volume of STELARA to be added (discard 26 mL sodium chloride for each vial of STELARA needed, for 2 vials- discard 52 mL, for 3 vials- discard 78 mL, 4 vials-discard 104 mL). Alternatively, a 250 mL infusion bag containing 0.45% Sodium Chloride Injection, USP may be used.
  3. Withdraw 26 mL of STELARA from each vial needed and add it to the 250 mL infusion bag. The final volume in the infusion bag should be 250 mL. Gently mix.
  4. Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration or foreign particles are observed.
  5. Infuse the diluted solution over a period of at least one hour. Once diluted, the infusion should be completely administered within eight hours of the dilution in the infusion bag.
  6. Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer).
  • Do not infuse STELARA concomitantly in the same intravenous line with other agents.
  1. STELARA does not contain preservatives. Each vial is for single use only. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements.

Storage:

If necessary, the diluted infusion solution may be kept at room temperature up to 25°C (77°F) for up to 7 hours. Storage time at room temperature begins once the diluted solution has been prepared. The infusion should be completed within 8 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). Do not freeze. Discard any unused portion of the infusion solution.

10. Overdosage

Single doses up to 6 mg/kg intravenously have been administered in clinical studies without dose-limiting toxicity. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment be instituted immediately.

16.2. Storage and Handling

STELARA vials and prefilled syringes must be refrigerated at 2°C to 8°C (36°F to 46°F). Store STELARA vials upright. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.

If needed, individual prefilled syringes may be stored at room temperature up to 30°C (86°F) for a maximum single period of up to 30 days in the original carton to protect from light. Record the date when the prefilled syringe is first removed from the refrigerator on the carton in the space provided. Once a syringe has been stored at room temperature, it should not be returned to the refrigerator. Discard the syringe if not used within 30 days at room temperature storage. Do not use STELARA after the expiration date on the carton or on the prefilled syringe.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.